By admin 
CureSearch for Children’s Cancer has officially announced that Dr. Robbie Majzner of the Dana-Farber Cancer Institute is the recipient of the 2026 CureSearch Catapult Award, a prestigious grant designed to accelerate the transition of laboratory breakthroughs into life-saving clinical treatments. This $2 million investment, co-funded in partnership with the Jeff Gordon Children’s Foundation, will provide the necessary resources to launch a Phase I clinical trial for a pioneering chimeric antigen receptor (CAR) T-cell therapy. The trial specifically targets children and young adults diagnosed with relapsed or refractory neuroblastoma, a patient population that currently faces a significant lack of effective therapeutic options and a dauntingly low survival rate.
The Catapult Award serves a critical function in the landscape of medical research by addressing the "translational gap," often referred to in scientific circles as the "valley of death." This is the precarious stage where promising laboratory discoveries frequently stall due to a lack of funding for the expensive and complex transition into human clinical trials. By providing substantial financial backing at this juncture, CureSearch aims to ensure that high-potential innovations reach the bedside of pediatric patients who have exhausted standard protocols.
The Challenge of High-Risk Neuroblastoma
Neuroblastoma is a cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands, which have similar origins to nerve cells. It is the most common extracranial solid tumor found in children, accounting for approximately 7% to 10% of all childhood cancers. Despite its relatively low incidence compared to adult cancers, its impact is disproportionately severe, contributing to more than 10% of all pediatric oncology deaths.
For patients diagnosed with high-risk neuroblastoma, the prognosis remains grim. Despite aggressive multi-modal treatment regimens—which typically include high-dose chemotherapy, surgical resection, radiation therapy, and stem cell transplants—the five-year survival rate lingers below 50%. Furthermore, for those who do achieve remission, the risk of relapse is high. Once the disease returns or becomes refractory to conventional treatment, the medical community has historically had very few tools left to combat the progression of the tumor. Beyond the immediate threat to life, survivors of high-risk neuroblastoma often endure lifelong "late effects," including hearing loss, cardiac issues, secondary cancers, and significant psychological trauma resulting from the intensity of the treatment.
Revolutionizing Immunotherapy: The Successes and Hurdles of CAR T-Cells
In recent years, immunotherapy has emerged as a fourth pillar of cancer treatment, alongside surgery, chemotherapy, and radiation. CAR T-cell therapy, in particular, has revolutionized the treatment of hematologic malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma. This process involves extracting a patient’s own T-cells—the "soldiers" of the immune system—and genetically engineering them in a laboratory to express a chimeric antigen receptor. This receptor allows the T-cells to recognize and bind to specific proteins on the surface of cancer cells, enabling the immune system to seek out and destroy the malignancy with high precision.
However, translating the success seen in blood cancers to solid tumors like neuroblastoma has proven exceptionally difficult. Solid tumors present a hostile microenvironment that can suppress immune activity. Furthermore, unlike the liquid environment of the bloodstream, solid tumors are physical masses that T-cells must penetrate and survive within. One of the primary reasons CAR T-cell trials for neuroblastoma have historically fallen short is a phenomenon known as T-cell exhaustion. When T-cells are constantly stimulated by the presence of a tumor, they can become "tired" or dysfunctional, losing their ability to proliferate and sustain an attack against the cancer.
Technical Innovation: The Role of GD2 and ZAP70
The research led by Dr. Robbie Majzner at Dana-Farber Cancer Institute seeks to solve the exhaustion problem through a novel engineering approach. The therapy focuses on targeting GD2, a disialoganglioside that is highly expressed on the surface of almost all neuroblastoma cells but has limited expression in normal healthy tissues. While GD2 has long been a target for monoclonal antibodies and earlier generations of CAR T-cells, those treatments have often been limited by the aforementioned lack of persistence.
Dr. Majzner’s team has redesigned the internal signaling architecture of the CAR T-cell. By incorporating a signaling protein called ZAP70, the researchers aim to mimic the natural, robust signaling of a healthy immune cell more closely. In preclinical models, this next-generation "ZAP-CAR" demonstrated a superior ability to remain active over extended periods. Unlike traditional models where the T-cells might burn out after the initial encounter with the tumor, these redesigned cells showed improved persistence and a sustained anti-tumor response. Additionally, the preclinical data suggests a potentially improved safety profile, reducing some of the inflammatory risks associated with rapid T-cell activation.
Chronology of Development and Clinical Transition
The journey of this therapy began in the laboratory, where Dr. Majzner and his colleagues spent years dissecting the molecular pathways that lead to T-cell failure. Through iterative testing in cell cultures and animal models, they identified that the standard signaling molecules used in first- and second-generation CARs were often too "noisy," leading to premature exhaustion.
The timeline for the project is now moving into its most critical phase. Following the successful completion of preclinical validation, the 2026 CureSearch Catapult Award provides the capital necessary to manufacture the clinical-grade viral vectors and T-cells required for human use. The upcoming Phase I trial will be a dose-escalation and safety study. Researchers will monitor the first cohort of pediatric and young adult patients to determine the maximum tolerated dose and to observe how long the engineered cells survive within the human body.
This transition from "bench to bedside" is a rigorous process involving oversight from the Food and Drug Administration (FDA) and Institutional Review Boards (IRB). The $2 million investment covers not only the clinical trial costs but also the complex correlative studies—biopsies and blood tests—that will allow scientists to see exactly how the ZAP-CAR cells are interacting with the neuroblastoma tumors in real-time.
Official Perspectives on the Investment
The leadership at CureSearch and the research team at Dana-Farber have expressed a shared sense of urgency regarding this project. Dr. Robbie Majzner emphasized the limitations of current technologies, noting that existing GD2-targeted therapies often fail in patients with a high tumor burden.
"Current GD2 CAR T cells only work in patients with small amounts of disease," Dr. Majzner stated. "We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models, and this trial will allow us to bring this advanced therapy to the children who need it most. The CureSearch Catapult Award is vital to our mission; it gives us the momentum to catapult this science out of the lab and directly to the forefront of patient care."
Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch, highlighted the strategic nature of the award. "One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," Myers said. "Through the Catapult Award, CureSearch helps move innovative therapies from the laboratory into clinical trials. Dr. Majzner’s work exemplifies the bold, high-potential research we were created to support."
Collaborative Philanthropy and Institutional Support
The funding for this award is a result of a strategic partnership between CureSearch for Children’s Cancer and the Jeff Gordon Children’s Foundation. Jeff Gordon, the four-time NASCAR Cup Series champion, has been a long-time advocate for pediatric cancer research, focusing his foundation’s efforts on improving access to less toxic and more effective treatments. This collaboration underscores a growing trend in the non-profit sector where organizations pool resources to fund high-stakes, high-reward "moonshot" projects that might be deemed too risky for traditional government grants.
Dana-Farber Cancer Institute, where the trial will be centered, is a world-renowned leader in oncology research. The institute’s infrastructure provides the necessary specialized cell-manufacturing facilities (GMP labs) required to produce personalized CAR T-cell therapies, ensuring that the transition from the Catapult Award announcement to patient enrollment is as seamless as possible.
Broader Implications for the Future of Oncology
The implications of Dr. Majzner’s research extend beyond the treatment of neuroblastoma. If the ZAP70 signaling architecture proves successful in human trials, it could provide a blueprint for treating other "cold" solid tumors that have previously been resistant to immunotherapy. GD2 is also expressed in other pediatric cancers, such as osteosarcoma and certain types of brain tumors (like diffuse intrinsic pontine glioma or DIPG), as well as some adult cancers like small cell lung cancer and melanoma.
Success in this trial would validate a new method of preventing T-cell exhaustion, potentially opening the door for a new generation of immunotherapies across the entire spectrum of oncology. By focusing on the fundamental mechanics of how immune cells signal and survive, the research moves the field away from broad-spectrum treatments toward highly sophisticated, durable, and personalized medicine.
As the 2026 Phase I trial approaches, the pediatric oncology community remains watchful. For the families of children with relapsed neuroblastoma, this research represents more than just scientific progress; it represents a tangible hope for a future where a high-risk diagnosis is no longer a definitive prognosis of poor outcomes. Through the strategic deployment of the Catapult Award, CureSearch continues to position itself as a pivotal force in the global effort to end childhood cancer.
